PRIME® launch Practical Toolkit for Building a Successful Partnership with High-Risk Hepatitis C Patients.

29 Aug 2019 Lucy Ferrier

Leading healthcare education and research company PRIME® has launched a practical toolkit aimed at aligning patients and providers in the prevention and treatment of hepatitis C. They have partnered with the World Hepatitis Alliance (WHA), the Achieve Coalition, British Viral Hepatitis Group, British Association for the Study of the Liver (BASL), Grupo de Ativistas em Tratementos (GAT), and Prometheus in an effort to reach global elimination of the virus by 2030.

The practical toolkit was created to fill a gap in accessible and user-centric guidance on the testing and treatment of hepatitis C. It has been designed to support patients – including those from marginalised populations – and medical practitioners in effectively engaging in testing, linkage, and treatment through coproduction to motivate patients toward self-care and positive health behaviours, including testing, treatment initiation, adherence, and risk reduction. Dr. Stephan Walcher, member of the Board of Directors for the European Opiate Addiction Treatment Association and Director of CONCEPT – Center for Addiction Treatment, said: “A lot of evidence has been compiled since the release of the first direct-acting antivirals, leading to adapted or newly issued guidelines. However, there has been a lack of simple, practical, and user-targeted handouts—something that both health care providers and patients can really work with”.

"There has been a lack of simple, practical, and user-targeted handouts—something that both health care providers and patients can really work with”.

The toolkit contains step-by-step guides to facilitate overcoming stigma and increasing patient engagement in screening, treatment, and self-care. It also includes a brief overview of hepatitis C treatment for key groups, including people who inject drugs (PWID), men who have sex with men (MSM), people in prison (PIP), and migrants. It is available in English, French, German, Italian and Spanish to maximise its accessibility and use across a variety of settings in Europe, including primary care clinics, drug treatment centres, medically supervised injecting centres, street-based outreach programs, prisons, and criminal justice settings.

“Patient-centred communication is fundamental in eliminating hepatitis C, and I expect that these new tools will play an important role in engaging patients in effective conversations that foster strategic action toward hepatitis C testing, treatment, adherence, and risk reduction,” said Professor Jeffrey V Lazarus, PhD, MIH, MA, Faculty of Medicine, Barcelona Institute for Global Health (ISGlobal).